Core Viewpoint - Major shareholders of Beijing Ruimait Medical Technology Co., Ltd. plan to reduce their holdings, with specific details on the number of shares and the percentage of total shares being disclosed [1][2]. Shareholder Reduction Plans - Nengjin Co., Ltd. and its concerted actions plan to reduce their holdings by up to 888,325 shares, representing 1% of the total share capital, within three months after 15 trading days from the announcement [1]. - Zhuhai Hexuan Investment Center and its concerted actions plan to reduce their holdings by up to 2,666,169 shares, representing 3% of the total share capital, within the same timeframe [2]. Shareholding Structure - As of June 18, 2025, the total share capital of the company is 88,872,320 shares, with 727,680 shares already repurchased by the company [2]. Compliance and Commitments - Shareholders have made commitments regarding the lock-up period and reduction intentions, ensuring compliance with relevant laws and regulations [4][5]. - The shareholders have also committed to not seeking control of the company within 36 months post-issuance [7].

Investment Rating - The report assigns a "Buy" rating for the company, with a target price of 94.15 CNY based on a 35x P/E ratio for 2025 [3][5]. Core Insights - The company is positioned as a leading player in the domestic home respiratory machine market, with significant growth potential in both domestic and international markets. The recovery in sales is expected as inventory issues clear up, particularly in the home respiratory machine segment [2][9]. - The global demand for chronic respiratory disease treatment is substantial, with a changing competitive landscape that has allowed the company to increase its market share significantly [9][40]. - The company has established a strong product quality comparable to international brands and is expanding its distribution channels both domestically and internationally [9][40]. Financial Forecast and Investment Recommendations - The company is projected to achieve earnings per share of 2.69 CNY, 3.59 CNY, and 4.57 CNY for the years 2025, 2026, and 2027, respectively. Revenue is expected to recover with a growth rate of 27.1% in 2025 [3][4]. - The financial outlook indicates a recovery in revenue and profit margins, with a notable increase in the contribution from consumables alongside the growth in respiratory machine sales [3][4][30]. Company Overview - Founded in 2001, the company has become a leader in the domestic home respiratory machine industry, with significant international expansion since obtaining FDA certification in 2012 [9][14]. - The company has experienced rapid growth, particularly during the COVID-19 pandemic and following the recall of Philips products, which has allowed it to capture market share [9][25]. Market Dynamics - The global market for home respiratory machines is expected to grow significantly, driven by increasing awareness of health issues and rising healthcare investments. The market size for home non-invasive respiratory machines was estimated at 2.78 billion USD in 2020 [57]. - The company has seen its market share in the domestic market rise to 30.6% by 2023, positioning it as the leading domestic brand [69][74]. Product and Service Strategy - The company offers a comprehensive range of products, including home non-invasive respiratory machines, ventilation masks, and oxygen concentrators, supported by a robust health management platform [17][40]. - The company is actively expanding its product offerings and market presence, including a recent strategic partnership to develop new respiratory products [39].

Core Viewpoint - The major shareholders of Ruimai Te (301367.SZ) have announced plans to reduce their holdings, which may impact the stock's performance in the market [1][2]. Shareholder Reduction Plans - Nengjin Company and its concerted action partner, Guangzhou Jinyuan, plan to reduce their holdings by up to 888,325 shares, representing 1% of the total share capital, within three months after the announcement [1]. - Hehan Investment and its concerted action partners, Shengmin Chuangtou and Nanjing Hehao, plan to reduce their holdings by up to 2,666,169 shares, representing 3% of the total share capital, within the same timeframe [2]. Shareholding Structure - Nengjin Company holds 4,480,795 shares (5.00% of total shares) and Guangzhou Jinyuan holds 753.325 shares (0.84% of total shares) [3]. - Hehan Investment holds 11,155,686 shares (12.45% of total shares), while Shengmin Chuangtou holds 5,373,515 shares (6.00% of total shares) and Nanjing Hehao holds 358.589 shares (0.40% of total shares) [3]. Reduction Methods and Quantities - Nengjin Company plans to reduce up to 135,000 shares through centralized bidding, while Guangzhou Jinyuan plans to reduce up to 753.325 shares [5]. - Hehan Investment plans to reduce up to 530.134 shares through centralized bidding, and Shengmin Chuangtou plans to reduce up to 1,777,446 shares through block trading [5]. Market Context - Ruimai Te is currently in a state of share price decline, indicating a potential market challenge for the company [9].

证券代码：301367 证券简称：瑞迈特 公告编号：2025-044 北京瑞迈特医疗科技股份有限公司 关于持股5%以上股东及其一致行动人 减持股份的预披露公告 公司股东能金有限公司及其一致行动人广州市金垣创业投资合伙企业（有限 合伙）、珠海合晅投资中心（有限合伙）及其一致行动人上海盛旻创业投资合伙 企业（有限合伙）和南京合灏创业投资企业（有限合伙）保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、合计持有本公司股份 5,234,120 股（占本公司总股本比例 5.84%）的股东 能金有限公司及其一致行动人广州市金垣创业投资合伙企业（有限合伙）计划在 自本减持计划公告之日起 15 个交易日后的 3 个月内以集中竞价方式或大宗交易 方式减持本公司股份累计不超过 888,325 股，占本公司总股本比例 1%（总股本 已剔除公司回购专用账户中的股份数量，下同）。 2、合计持有本公司股份 16,887,790 股（占本公司总股本比例 18.85%）的股 东珠海合晅投资中心（ ...

Group 1 - The core point of the announcement is that two major shareholders plan to reduce their holdings in the company through trading methods within a specified timeframe [1] Group 2 - Shareholder Enerjin Limited and its concerted parties plan to reduce their holdings by up to 888,300 shares, which represents 1% of the total share capital [1] - Shareholder Zhuhai Huanxian Investment Center and its concerted parties plan to reduce their holdings by up to 2,666,200 shares, which represents 3% of the total share capital [1] - The reason for the reduction in holdings is due to the shareholders' own financial arrangements [1]

Group 1 - The stock price of Ruimaite (301367.SZ) closed at 79.36 yuan, with a decline of 2.17%, currently below the issue price [1] - Yihe Jiaye was listed on the Shenzhen Stock Exchange's ChiNext on November 1, 2022, with a public offering of 16 million shares, accounting for 25% of the total share capital after issuance, at an issue price of 119.88 yuan per share [1] - The total amount raised by Yihe Jiaye was 191.808 million yuan, with a net amount of 173.82674 million yuan, exceeding the originally planned fundraising by 100.02698 million yuan [1] - The original fundraising plan was 73.79976 million yuan, intended for projects including the production of 300,000 ventilators and 3.5 million sets of accessories, marketing network and brand building, medical equipment R&D center, and working capital [1] - The underwriting institution for Yihe Jiaye was China International Capital Corporation (CICC), with representatives Chen Tingting and Xie Xianming [1] - The total issuance expenses amounted to 18.30202 million yuan, including underwriting and sponsorship fees of 15.71582 million yuan [1] - On May 22, 2024, Yihe Jiaye announced a dividend plan of 10 yuan (pre-tax) per 10 shares, with a bonus issue of 4 shares, with the ex-dividend date set for May 29, 2024 [1] Group 2 - On May 21, 2025, Yihe Jiaye announced a change of company name and stock abbreviation, changing from "Beijing Yihe Jiaye Medical Technology Co., Ltd." to "Beijing Ruimaite Medical Technology Co., Ltd." while the stock code "301367" remains unchanged [2]

Group 1 - The project led by Tianjin Yihejiaye Medical Technology Co., Ltd. won the first prize of Tianjin Science and Technology Progress Award for the research and clinical application of non-invasive respiratory system key technologies [1] - Respiratory diseases have become the third largest chronic disease in China, following cardiovascular diseases and diabetes, with chronic obstructive pulmonary disease and obstructive sleep apnea being the most typical [1] - The non-invasive ventilator is currently the most effective medical device for treating respiratory diseases, with significant technological barriers existing in China compared to developed countries [1] Group 2 - The project achieved breakthroughs in core technologies, key equipment, system platforms, and international standards, possessing complete independent intellectual property rights [1] - A multi-center randomized controlled study was conducted in collaboration with 30 hospitals, focusing on the impact of high-intensity and low-intensity non-invasive positive pressure ventilation on the need for intubation in patients with acute exacerbations of chronic obstructive pulmonary disease [1] - The research results will be published in the Journal of the American Medical Association in 2024 [1] Group 3 - The project team also made advancements in the respiratory chronic disease management system, creating a respiratory data management cloud platform based on data from over 300,000 active users of non-invasive respiratory therapy [2] - The cloud platform connects patients, their families, and doctors, allowing real-time monitoring of sleep-related respiratory data and enabling remote adjustment of treatment parameters by doctors [2] - In 2023, the global market share of Ruimai Te's home non-invasive ventilator was 12.4%, ranking second, while its domestic market share was 30.6%, ranking first among domestic brands [2] Group 4 - As of January 2025, the cumulative sales of Ruimai Te's home ventilators exceeded 3 million units, and the cumulative sales of ventilation masks surpassed 10 million units [2]

Company Overview - Beijing RMT Medical Technology Co., Ltd. was established in 2001 and successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2022 [2] - The company specializes in providing comprehensive treatment solutions for OSA and COPD patients, focusing on home non-invasive ventilators and ventilation masks [2] - RMT is the first domestic company to have non-invasive ventilator products certified by the FDA, with sales in over 100 countries [2] Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents [3] - The company also has 202 valid overseas patents, including 39 in the United States and 30 in Europe [3] Financial Performance - In Q1 2025, the company's overseas revenue reached 170 million CNY, a year-on-year increase of 35.48%, while domestic revenue was 96 million CNY, with a quarter-on-quarter growth of 48.79% and a year-on-year growth of 43.03% [4] - The gross margin for domestic operations was 51.51%, and for overseas operations, it was 48.47%, with both showing an increase compared to the previous quarter [4] Product Launches and Market Strategy - The newly launched P5 series ventilators are primarily targeted at domestic hospital channels, which have a relatively high gross margin [4] - The introduction of the RMT oxygen bottle marks a strategic shift towards the consumer goods market, enhancing brand influence and market share [5] Brand Development - The company's rebranding to "RMT" signifies a strategic alignment between product and capital markets, aiming to enhance brand value [5] - The name "RMT" reflects the company's commitment to respiratory health and smart technology, creating a unified identity across products and capital markets [5] Market Expansion - The company has made adjustments to domestic channel policies and sales strategies, resulting in improved revenue and gross margins in Q1 2025 [5] - In Europe, the company has completed the construction of its cloud platform and is onboarding agents, laying the groundwork for future growth in the mainstream medical insurance market [5]

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established in 2001 and launched its first multi-channel sleep monitor in 2003. The company went public on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2022 [2][3]. - The company specializes in providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management [2][3]. - Ruimait is a leading domestic company in home non-invasive ventilators and masks, with products sold in over 100 countries and regions, holding multiple certifications including NMPA, FDA, and CE [2][3]. Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents. It also has 202 valid overseas patents [3]. Market Position - Ruimait's home non-invasive ventilators hold a 30.6% market share in China, ranking first, and a 12.4% share globally, ranking second in the industry [4][5]. Brand Strategy - The rebranding to "Ruimait" signifies a strategic alignment between product identity and capital market perception, enhancing brand value and market penetration [4][5]. - The name "Ruimait" combines "respiratory" and "smart," reflecting the company's commitment to respiratory health and innovative technology [5]. Product Development - The launch of the Ruimait oxygen bottle marks the company's entry into the consumer goods market, featuring a unique mechanical valve design that enhances oxygen utilization [6]. - The collaboration with Shenzhen Hanyu Pharmaceutical Co., Ltd. aims to develop new products for health consumer channels, targeting mild sleep disorder populations [6][7]. Market Expansion - The company is enhancing its domestic channel strategies and has seen improvements in revenue and gross margin in the first quarter [7][8]. - In Europe, the company has established a cloud platform and onboarded over 20 agents, laying the groundwork for future growth in the mainstream medical insurance market [8].

Core Viewpoint - The company has shown a recovery in performance with Q1 2025 results exceeding expectations, driven by improved order fulfillment in the U.S. market and ongoing domestic growth initiatives [1][3][10] Financial Performance - For 2024, the company reported revenue of 843 million yuan (down 24.85%), net profit attributable to shareholders of 155 million yuan (down 47.74%), and net profit excluding non-recurring items of 92 million yuan (down 61.79%) [2][3] - In Q1 2025, revenue reached 265 million yuan (up 38.11%), net profit attributable to shareholders was 72 million yuan (up 44.11%), and net profit excluding non-recurring items was 60 million yuan (up 43.18%) [2][4] Market Outlook - The company anticipates continued growth in Q2 2025, particularly in the U.S. market, as the low base effect from the previous year supports performance [1][5] - The company plans to enhance brand promotion and channel development in both domestic and international markets throughout the year [1][5][10] Business Segmentation - Revenue from home respiratory therapy products in 2024 was 527 million yuan (down 38.15%), while consumables revenue was 284 million yuan (up 46.22%) [4] - In Q1 2025, home respiratory therapy revenue was 176 million yuan (up 62.80%), and consumables revenue was 81 million yuan (up 7.46%) [4][9] Brand Development - The company changed its name from "怡和嘉业" to "瑞迈特" on May 21, aiming to enhance brand influence and align its corporate identity with its core product offerings [2][5][6] R&D and Innovation - The company is committed to maintaining high levels of R&D investment to improve product performance and expand market share [1][5][10] - Future innovations in respiratory products are expected to leverage AI and brain-machine interface technologies for enhanced functionality [6] Incentive Plans - The company announced a stock incentive plan for 2025, aiming to grant up to 704,000 restricted shares to 54 key personnel, with performance targets set for revenue growth [7]